Study | Location | Study design | Evidence level(16) | Number of patients | Male (%) | Age (years) | Follow-up (months) | |||
---|---|---|---|---|---|---|---|---|---|---|
 |  |  |  | AW | OW | AW | OW | AW | OW |  |
Peres (2016) [23] | Brazil | RCT | 1 | 10 | 11 | 7 (70.0) | 7 (63.6) | 42 (11–66)¶ | 45.4 (19–74)¶ | Min 24 |
Balabaud (2007 [24] | France | Cohort | 3 | 21 | 19 | 31 (77.5) | 31 (77.5) | 49 ± 20 (19–81)¶ | 22 ± 2 (12–96)¶ | |
Böhler (2016) [25] | Austria | Cohort | 3 | 41 | 29 | 27 (65.9) | 19 (65.5) | 49 (30–64)¥ | 71 (65–78)¥ | 12¥ (12–15) |
Johns (2017) [26] | Australia | Cohort | 3 | 119 | 42 | 80 (67.2) | 28 (66.7) | 57.5 (15.8)Â¥ | 65.8 (16.0)Â¥ | - |
Kalem (2018) [27] | Turkey | Cohort | 3 | 13 | 11 | 8 (61.5) | 6 (54.5) | 56.6 ± 14.9¶ | 59.5 ± 17.2¶ | 6 |
Sabater-Martos (2021) [28] | Spain | Cohort | 3 | 12 | 15 | 18 (66.7) | 64.8 (30–89) | Min 12 | ||
Wirtz (2001) [29] | Germany | Cohort | 3 | 27 | 24 | 25 (49.0) | 59.7 (21–94)¶ | 26.4¶ |